News & Announcements
Read the latest news from Northwestern University Feinberg School of Medicine’s Department of Microbiology-Immunology. The links below take you to articles where you can learn more about our faculty’s latest achievements, awards and honors.
Northwestern Medicine scientists have developed an engineered probiotic capable of detecting inflammatory bowel disease, according to a study published in the Proceedings of the National Academy of Sciences.
Northwestern Medicine scientists have discovered how HIV hijacks intracellular processes to proliferate and contribute to neurodegeneration, according to a new study published in Nature Communications.
Northwestern Medicine investigators have developed a novel nanoparticle treatment for glioblastoma, according to a study published in Nature Communications.
Alan Hauser, MD, PhD, vice chair of Microbiology-Immunology, has been named the new director of Feinberg’s Medical Scientist Training Program (MSTP), effective April 15.
Feinberg scientists continue to investigate the lasting impact of the COVID-19 pandemic, from utilizing sentinel surveillance to monitor SARS-CoV-2 transmission rates to developing new approaches to monoclonal antibody therapy.
Targeting cellular post-transcription mechanisms in the CD73 ectoenzyme may promote anti-tumor immunity and slow cancer progression in triple-negative breast cancer, according to a recent Northwestern Medicine study.
Increased levels of the antibody immunoglobulin A (IgA) are correlated with the manifestation of several diseases and African ancestry, according to findings published in Nature Communications.
Northwestern Medicine scientists have identified a new therapeutic target against tumor cells and developed a compound which slows tumor growth and bolsters immune response.
The presence of food-specific IgA antibodies in the gut does not prevent peanut or egg allergies from developing in children, according to a Northwestern Medicine-led study published in Science Translational Medicine.
Targeting internal proteins instead of spike proteins may be a promising strategy for monoclonal antibody therapy to combat SARS-CoV-2, the virus that causes COVID-19.
Northwestern Medicine investigators have uncovered novel regulatory mechanisms that promote bacterial survival, according to findings published in PNAS.